FLT3 and leukemia: Although AML with FLT3 mutation is not included in the WHO classification as a distinct entity, it is the most commonly (~30% of AML) mutated gene in AML and its presence predicts an unfavorable prognosis.23FLT3 internal tandem duplication (FLT3-ITD) mutations result in a constitutively active FLT3, a transmembrane tyrosine kinase, which in turns results in the growth and proliferation of leukemia cells.24 Because of its association with high rates of relapse, allogeneic hematopoietic stem cell transplant (SCT) is generally recommended in first remission.